|Paul Volberding & others, "The Evolution of HIV/AIDS Therapies: A Conversation", 2012, Chemical Heritage Foundation|
In 1983, Volberding founded the first inpatient ward for persons with AIDS in the San Francisco General Hospital. He worked on early clinical trials to evaluate antiretroviral therapy in HIV infection, and has served on the two major guidelines panels for antiretroviral therapy, addressing issues such as the optimal timing of treatment in early HIV infection when no symptoms are evident.
In 2001 Volberding left the SF General Hospital to become chief medical officer at the San Francisco VA Medical Center, at which time he also became vice chairman of the department of medicine at the University of California, San Francisco (UCSF). He went on to become to co-director of the Center for AIDS Research (CFAR) at UCSF and the Gladstone Institute of Virology and Immunology. In February 2012, he became the director of UCSF's AIDS Research Institute, and Director of Research for UCSF Global Health Science.
Volberding is also the co-editor of the Journal of Acquired Immune Deficiency Syndromes.He sits on the boards of IAS-USA, Pangaea Global AIDS Foundation, and advises at the Accordia Global Health Foundation, as well as many other activities to support research in HIV and global health.
- Miller, Talea (6 June 2011). "Essay: Treating the Earliest Cases of AIDS". pbs.org. Retrieved 2 July 2011.
- "Paul Volberding Takes Leading Roles with UCSF’s ARI, Global Health Sciences". UCSF.edu News Center. University of California, San Francisco. 17 February 2012. Retrieved 7 March 2012.
- Perlman, David (25 January 2001). "Top AIDS Expert Quits S.F. General For VA Hospital". San Francisco Chronicle. Retrieved 3 July 2011.
- "Paul Volberding". thehivstoryproject.org. The HIV Story Project. Retrieved 7 March 2012.